Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.38−0.22 (-2.29%)
Close on Nov 18, 2026Market cap $620.70MP/E –Yield –
Bicara Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bicara Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$237.03M. For fiscal 2025 it was -$155.60M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$155.60M | – |
| FY2024 | Dec 31, 2024 | -$82.39M | – |
| FY2023 | Dec 31, 2023 | -$39.89M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$75.71M | – |
| Q2 FY2026 | Jun 30, 2026 | -$59.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$60.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$32.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.64M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.37M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.69M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.53M | – |
See a number that looks wrong?